WASHINGTON — Growth in the ophthalmic device market will accelerate over the next 2 to 3 years due to the reduction of COVID-19-driven backlogs, according to a presenter here.
“Innovation has returned and will continue,” Chuck Adams, of Citi, said during a keynote lecture at Eyecelerator@ASCRS.
Adams said to expect increased emerging market penetration and the premiumization of implantable and contact lenses. While the current conflict between Russia and Ukraine is concerning, he said, it should not present a meaningful headwind for the majority of ophthalmic device players.